Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.48 |
| ▸ | ACHE | P22303 | 4/20 | 0.47 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
| ▸ | PNMT | P11086 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13264430 | 0.89 | LMNA (0.47) | LMNAPOLBSIGMAR1ACHEMC4R | |
| SCHEMBL13696609 | 0.87 | SIGMAR1 (0.52) | LMNAPOLBSIGMAR1ACHEMC4R | |
| SCHEMBL10142868 | 0.83 | SIGMAR1 (0.55) | LMNAPOLBSIGMAR1ACHEMC4R | |
| SCHEMBL31651763 | 0.83 | SIGMAR1 (0.47) | LMNAPOLBSIGMAR1ACHEMC4R | |
| SCHEMBL14211674 | 0.83 | SIGMAR1 (0.47) | LMNAPOLBSIGMAR1ACHEMC4R | |
| SCHEMBL20756828 | 0.82 | MEN1 (0.42) | LMNAPOLBSIGMAR1ACHEMC4R | |
| SCHEMBL8546671 | 0.81 | MEN1 (0.51) | LMNASIGMAR1MEN1NPC1RAB9A | |
| SCHEMBL23858257 | 0.79 | SIGMAR1 (0.50) | LMNAPOLBSIGMAR1ACHEMC4R | |
| SCHEMBL12002187 | 0.79 | SIGMAR1 (0.50) | LMNAPOLBSIGMAR1ACHEMC4R | |
| SCHEMBL8344719 | 0.79 | LMNA (0.50) | LMNAPOLBSIGMAR1ACHEMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181240-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-8999978-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20130131054-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131054-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | LMNA 4777/4885POLB 4782/4885SIGMAR1 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.